Introduction
Focal adhesion kinase (pp125 FAK ) is a tyrosine kinase that localizes to cellular focal adhesions and associates with a number of other proteins such as integrin adhesion receptors (reviewed in Richardson and Parsons, 1995) , focal adhesion components, such as paxillin and talin (Turner and Miller 1994; Schaller and Parsons, 1994; Tachibana et al., 1995; Chen et al., 1995) , and signalling proteins including protein tyrosine kinases of the Src family (Cobb et al., 1994; Xing et al., 1994; Cary et al., 1996; Fincham and Frame, 1998) , phosphatidyl inositol (PI) 3-kinase , the Rho GTPase activating protein Graf (Hildebrand et al., 1996) and adaptor molecules, including GRB2 (Schlaepfer et al., 1994; Kharbanda et al., 1995) and p130 CAS (Harte et al., 1996; Polte and Hanks, 1995) . Although the precise regulation and biological function of pp125 FAK remain to be determined, its diverse range of binding partners places it at a crossroads between adhesion and growthregulatory signal transduction.
Studies addressing the role of pp125 FAK in cell adhesion suggest that it can contribute to both focal adhesion assembly (Richardson and Parsons, 1996; Richardson et al., 1997) and focal adhesion turnover (Fincham et al., 1995; Ilic et al., 1995; Fincham and Frame, 1998). Pp125 FAK is extensively regulated by tyrosine phosphorylation, which might, in turn, control the processes of focal adhesion assembly and disassembly that contribute to cell motility. In keeping with this, there is strong evidence that pp125
FAK is a key regulator of cell migration. Speci®cally, cells derived from pp125
FAK 7/7 mouse embryos exhibit reduced migration as a result of impaired adhesion turnover (Ilic et al., 1995 (Ilic et al., , 1996 . Moreover, displacement of pp125 FAK from focal adhesions reduces cell migration (Gilmore and Romer, 1996) , whilst overexpression of pp125 FAK in CHO cells stimulates migration (Cary et al., 1996) , suggesting that the level of pp125 FAK protein may limit cell movement in some cell types.
Since the expression level of pp125 FAK may be a determinant of the rate of cell movement, and since elevated pp125 FAK may also enhance tumour cell survival (Frisch et al., 1996; Xu et al., 1996) , it is perhaps not surprising that a number of groups have found that pp125 FAK is up-regulated in cancer cells. In particular, pp125
FAK is elevated in cell lines from human melanomas, with pp125 FAK levels correlating with the rate of cell migration on ®bronectin (Akasaka et al., 1995) , in cervical carcinoma cell lines (McCormack et al., 1997) , in prostatic carcinoma tumours and cell lines (Tremblay et al., 1996) and in colon and breast tumours and cell lines (Owens et al., 1995) , the latter study inferring a link between Elevated fak gene copy number is also evident in sections from squamous cell carcinomas Figure 1 Localization of fak to chromosome 8q in proximity to the c-myc locus and its copy number gains in BICR31 and BICR6.
(a) Chromosomes were prepared from lymphocytes that were arrested in metaphase using colcimid and probed with both a DIGlabelled centromeric probe for chromosome 8 (visualized as red) and biotin-labelled fak probe (visualized as green). (b) Metaphase chromosome preparations from BICR31 and BICR6 were probed with both DIG-labelled c-myc and biotin-labelled fak. White arrows show fak and c-myc genes at the ends of isochromosomes. The chromosomes were stained with DAPI. (c) 5 m frozen squamous cell carcinoma tumour sections were probed with FITC-labelled fak (signals visualized as yellow). The nuclei were visualized as red. Cells within the sections act as internal controls (arrow points to nuclei with two copies of fak, whilst broken arrows point to tumour cell nuclei which contain more than two copies of fak pp125 FAK expression and tumour invasiveness. However, despite the mounting evidence that the expression of pp125 FAK is elevated in tumour-derived cell lines, the mechanism of up-regulation has not been addressed. Here we report that in malignant keratinocytes derived from squamous cell carcinomas (SCC), fak is upregulated at the genetic level and that this is often associated with increased expression of pp125 FAK protein. Furthermore, we observed increased fak gene dosage in a variety of cell lines derived from human lung, breast and colon tumours, including two cell lines in which fak was ampli®ed. In addition, the progression of colonic adenoma cells to carcinoma cells in vitro was accompanied by increased pp125 FAK expression and a copy number gain of the fak gene. Thus, we conclude that in many cells derived from human epithelial tumours, there is increased fak gene dosage which is often associated with increased pp125 FAK protein expression. Although the c-myc proto-oncogene is almost always co-ampli®ed or increased in copy number along with fak, increased expression of c-Myc protein was less frequently observed in the invasive cell lines we examined. These data, together with the important roles now de®ned for pp125 FAK in cell motility, invasion, growth and tumour cell survival, suggest that pp125 FAK could contribute to the selection pressure that results in the frequent increase in dosage or ampli®cation of the region of chromosome 8q that contains the fak and c-myc genes.
Results and discussion
Copy number gains of the fak locus in the BICR series of SCC-derived cell lines
The gene encoding pp125 FAK has previously been mapped to mouse chromosome 15 and to human chromosome 8 (Fioderek and Kay, 1995) . Linkage of fak to the protooncogene c-myc in the mouse suggested that human 8q24, where c-myc is located, is the likely site of the fak gene in the human genome (Fioderek and Kay, 1995) . To examine the fak gene in human tumourderived cell lines by¯uorescent in situ hybridization (FISH), we isolated a PAC clone containing fak sequences as described in the methods. We con®rmed that the fak gene mapped to the q arm of chromosome 8 and that normal lymphocytes had two copies of the gene ( Figure 1a) . Furthermore, FISH analysis of chromosome preparations from a number of malignant keratinocyte cell lines derived from SCCs of the head and neck (the BICR cell lines, Edington et al., 1995) demonstrated that these had more than two copies of the fak gene in a high percentage of nuclei and that it co-localized with c-myc, con®rming its position at human chromosome 8q24 (shown for BICR6 and BICR31 in Figure 1b ). In the examples shown, BICR6 and BICR31 have ®ve and four copies of both fak and c-myc respectively, and some of these are present at both ends of an isochromosome (shown by arrows in Figure 1b ). We found that all nine BICR cell lines examined had greater than two copies of both fak and cmyc (shown in Table 1 ). In addition, we observed elevated dosage of the fak gene in frozen sections of squamous cell carcinomas derived from head and neck (Figure 1c ), indicating that increased fak was not a consequence of tumour cell growth in culture and occurred in vivo during tumour progression.
Increased fak gene dosage is associated with increased protein expression in most cell lines
To compare the levels of pp125 FAK and c-Myc protein in the BICR cell lines, we carried out protein immunoblots. Protein concentrations were carefully determined and equal amounts of total cell lysate were separated by SDS ± PAGE, blotted and probed with pp125 FAK -or c-Myc-speci®c antibodies. With the exceptions of BICR16 and BICR63 (2/9 cell lines), the malignant keratinocytes examined (7/9 cell lines) displayed steady state levels of pp125 FAK protein that were elevated more than twofold above those in human normal keratinocytes (HNK). Although most cell lines had increased levels of pp125 FAK , there was no precise correlation between fak gene copy number and protein expression. This is exempli®ed by BICR6 and BICR16 which each have ®ve copies of the fak gene, but which express substantially dierent levels of pp125 FAK protein (Figure 2a and b) . Thus, although all of the BICR cell lines examined have increased fak gene copy number, and this may contribute to elevated protein expression in some cell lines, it does not necessarily lead to a related increase in protein in all cases. These observations imply that additional controls operate, in at least some malignant cell lines, to control the level of pp125 FAK protein. Amongst the BICR cell lines examined, there was considerable variation in c-Myc expression (Figure 2a and b). Only two cell lines BICR16 and BICR78 (2/9) displayed more than twofold elevated levels of c-Myc when compared to normal keratinocytes (Figure 2a and b). Thus, although the fak and c-myc genes are both similarly increased in copy number in the BICR cell lines, we found that pp125
FAK was elevated in 6/9 cell lines without an associated increase in c-Myc, indicating that the protein expression levels are not always co-ordinately regulated. These data further imply that c-Myc function is unlikely to provide the selection pressure for maintaining increased dosage of the region of 8q24 which contains fak and c-myc in many of the BICR cell lines examined, and suggests that pp125 FAK could be a potential driving force for maintaining these genetic changes in some tumour cells, at least in vitro. However, our data do not rule out roles for other genes at this locus in the frequent selection of copy number gains in malignant cells.
As a control for protein loading and to determine whether other proteins similarly¯uctuated in malignant keratinocytes, we examined the expression of the pp125 FAK homologue, PYK2 (Lev et al., 1995; Avraham et al., 1995; Sasaki et al., 1995) , which can substitute for some aspects of pp125 FAK signalling (Sieg et al., 1998) , and p42/ERK2, a protein kinase that is not generally regulated by¯uctuations in expression. We found no consistently altered expression of either protein in the BICR cell lines tested when compared to normal keratinocytes (Figure 2c ). fak gene copy number gains in cell lines from a variety of human epithelial tumour types
To test the generality of fak copy number gains, we carried out FISH analysis on archived chromosome preparations from cell lines derived from lung, breast and colon tumours. We found that 8/11 lung cancer cell lines, 6/6 colon cancer cell lines and 6/6 breast cancer cell lines had greater than two copies of fak per nucleus (Table 2 ). In addition, the fak gene was ampli®ed in two cell lines examined, Calu3 (lung) and HT29 (colon) tumour cells ( Figure 3 , Table 2 ). Although we were unable to compare the pp125 FAK protein levels in these cell lines with normal lung or colon cell controls, both cell lines expressed abundant pp125 FAK (not shown). Thus, many tumour-derived cell lines from a variety of epithelial tumour types have upregulated fak at the genetic level.
fak copy number gain accompanies the adenoma to carcinoma progression in an in vitro model of colon tumour development
To address the stage during tumour progression that fak was increased, we utilized an in vitro system that models the conversion from colonic adenoma to carcinoma. In this model, a cell line was derived from a large tubular adenoma with mild dysplasia (PC/AA). A clonogenic variant adenoma was established (AA/ C1) and a fully tumorigenic and invasive malignant cell line was derived by sequential chemical treatment and tissue culture procedures (AA/C1/SB10; model described in Williams et al., 1990; Brunton et al., 1997) . Both the cellular and molecular changes during this in vitro progression are similar to those that occur in vivo (Manning et al., 1991; Williams et al., 1993) , indicating that this is a relevant model to study colon cancer progression and the changes required for the transition to an invasive phenotype. Using FISH analysis, we showed that the clonogenic, non-invasive adenoma cell line AA/C1 had two copies of the fak gene ( Figure 4a) ; in contrast, the invasive carcinoma derivative AA/C1/ SB10 had three copies. Thus, acquisition of an additional copy of fak occurred during malignant conversion and did not occur at an earlier stage of tumour development, at least in this model. The timing of the increase in fak gene copy number was coincident with up-regulation of pp125 FAK protein expression (Figure 4b ) and the acquisition of an invasive phenotype (Brunton et al., 1997) . These data are consistent with the up-regulation of pp125
FAK not being required for tumour initiation, or other early stages of tumour development, but support its proposed role in the later acquisition of an invasive phenotype. In addition to fak, we again found that the carcinoma cells had an additional copy of c-myc, although no increase in the expression of c-Myc protein was obtained as the adenoma cells progressed to become invasive carcinoma cells in vitro (C Paraskeva, unpublished observation).
General discussion
The ®nding that pp125 FAK is often overexpressed in human tumours and tumour-derived cell lines, strongly suggests that this cell/ECM adhesion-linked tyrosine kinase might be involved in the development of invasive cancer. Here we have used FISH to con®rm that chromosome 8q is the genomic location of the fak gene and that it maps very close to the c-myc gene, de®ning its position at 8q24 where c-myc is known to reside. We further demonstrate that genetic mechanisms including copy number gains, ampli®cation and isochromosome formation involving the fak locus, are often associated with elevated pp125 FAK protein in human epithelial tumour cell lines and in tumours in vivo. This, together with the fact that pp125 FAK protein has been shown to be elevated in tumour tissues (Owens et al., 1995) , suggests that increased pp125 One possibility is that up-regulated pp125 FAK contributes to ECM-dependent tumour growth by mediating signalling from ®bronectin to the Ras/ MAP kinase cascade that is implicated in proliferation control (Schlaepfer et al., 1994) . Another potential role proposed for pp125 FAK is in making transformed cells able to grow in an anchorage-independent manner (Frisch et al., 1996) . As well as in anchorage-deprived cells, pp125 FAK can also act as a survival factor for adherent cells (Hungerford et al., 1996; Xu et al., 1996) and is speci®cally cleaved and inactivated by caspases during the apoptotic process (Crouch et al., 1996; Wen et al., 1997) . Thus, pp125
FAK may contribute to ECMdependent growth and survival of tumour cells under conditions in vivo that would be unfavourable for normal cells.
As well as tumour cell growth and survival, another likely role for elevated pp125 FAK in tumour cells is in the acquisition of an invasive phenotype. Cancer cell invasion is a complex process that requires cells to adhere and migrate through the underlying ECM.
Since pp125 FAK functions as a key regulator of ECMdependent cell migration (Ilic et al., 1995 (Ilic et al., , 1996 Gilmore and Romer, 1996; Cary et al., 1996) , and since endogenous levels of FAK expression can limit the rate of cell motility in some cell types (Cary et al., 1996) , it seems likely that elevated pp125 FAK in tumour cells may release normal constraints on the rate of cell motility, thus enhancing invasive potential. Consistent with this possibility, we found that the gain of an additional copy of the fak gene, which was associated with elevated pp125 FAK protein, occurred relatively late in an in vitro model of colon carcinoma development and was coincident with acquisition of an invasive phenotype (Brunton et al., 1997) .
The results presented here do not allow us to conclude whether neighbouring genes, including that encoding c-Myc, that are also increased in dosage or co-ampli®ed along with fak, contribute to malignant development. Our results with the BICR series of cell lines, and their normal keratinocyte counterparts, show that pp125
FAK protein is up-regulated to a greater or lesser extent in many tumour-derived cell lines. However, although c-myc is also up-regulated at the genetic level, increased expression of c-Myc protein was less frequently observed. Furthermore, although an FAK expression levels in the early colonic adenoma PC/AA, clonogenic adenoma AA/C1 and invasive carcinoma AA/C1/SB10 cell lines were determined by immunoblotting using anti-pp125 FAK -speci®c serum as probe. Quantitation was by scanning laser densitometry and is expressed as OD6mm 2 (arbitrary units)
additional copy of the c-myc gene was gained at the same stage as fak during colon carcinoma development in the in vitro model, there was no concomitant increase in the expression of c-Myc. Together, these data imply that fak, at least in some cells, is a stronger candidate than c-myc as the gene responsible for maintenance of increased dosage of this region of the genome. The frequent genetic up-regulation of fak that we observed in cell lines derived from lung, breast and colon cancers suggests that it could be an important event in the development of invasive epithelial tumours. This, together with the role of pp125 FAK as a regulator of cellular adhesion, motility, invasion, survival and cell growth, processes that are perturbed in cancer, implies that pp125 FAK may be intimately involved in tumorigenesis.
Materials and methods

Cell culture
Normal human keratinocytes (HNK) were prepared from human foreskin essentially as described in Parkinson et al. (1986) , except that type I-S trypsin inhibitor (Sigma Chemical Co., UK) was used instead of FCS-containing medium to neutralize trypsin. These normal cells and the BICR cell lines, which were derived from squamous cell carcinomas by a method modi®ed from that described in Rheinwald and Beckett (1981) , were grown on lethally irradiated NIH3T3 feeder cells in DMEM supplemented with 10% foetal bovine serum (FBS) and hydrocortisone (0.4 mg/ml). The AA/C1 colon adenoma and AA/C1/SB10 colon carcinoma cells were cultured in 3T3 conditioned medium ± DMEM with 10% FBS, insulin (0.2 units/m1) and hydrocortisone (1 mg/ml) ± as described in Brunton et al. (1997) .
Protein immunoblots
Cells were lysed in 10 mM Tris (pH 7.5), 1% Triton X-100, 0.5% NP40, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM NaPPi, 2 mM PMSF, 100 mM Na 3 VO 4 , 0.5 mM NaF and 0.1% aprotinin (Sigma). Extracts were assayed for protein content using the Micro BCA Protein Assay Kit (Pierce, USA) after clari®cation by high speed centrifugation at 48C. Lysates were boiled in high SDS (2.5%) sample buer and 25 mg total protein separated by discontinuous SDS ± PAGE (7.5% gel for pp125 FAK and 10% gel for c-Myc) under reducing conditions prior to transfer to nitrocellulose. Proteins were detected by probing with 1 : 500 dilution of anti-pp125 FAK (Transduction Laboratories, USA) or 1 : 100 dilution of anti-c-Myc serum (a gift from David Gillespie, Beatson Institute, Glasgow, UK) diluted in 5% non-fat milk in PBS/0.2% (v/v) Tween 20. Detection of bound antibody was by reaction with horseradish peroxidase-conjugated secondary antibody (Amersham, UK) and visualization was by enhanced chemiluminescence (Amersham, UK). Quantitation was by scanning laser densitometry using appropriate ECL exposures. p42/ERK2 and PYK2 were detected similarly after probing with 1 : 2000 anti-p42 (anti-C-terminal peptide rabbit polyclonal serum) or anti-PYK2 (Aniti, Cambridge, UK).
FISH analysis
Probe isolation cDNA encoding pp125 FAK (a gift from Alan Richardson and Tom Parsons) was radiolabelled with 32 -phosphate dCTP* and used to screen a human PAC library. Filters containing the human genomic library were obtained from the MRC Human Genome Mapping Project Resource. Filters were hybridized overnight at 658C in hybridization buer (56SSPE, 56Denhardt's, 0.5% SDS, 1 mg/ml yeast RNA type IV) containing 200 ng radiolabelled pp125 FAK cDNA. Positive clones were screened to isolate a PAC covering the region of the genome encoding pp125 FAK .
Chromosome preparation Chromosome preparations, probe labelling, in situ hybridization and visualization were as described previously (Murphy et al., 1995) using the Hybaid Omnislide system. The chromosome preparations from the lung, breast and colon cell lines that were analysed by FISH (results in Table 2 ) were from archived material. The c-myc and the chromosome 8 centromeric probes were obtained commercially (Appligene). Fluorescent images were captured using a digital camera on a Zeiss Axioscope. The number of signals was determined in more than 50 nuclei for each cell line and the mode and maximum number of copies of the fak gene were recorded. To examine tumour tissue, 5 m frozen sections of squamous cell carcinoma derived from head and neck were probed as described above. Nuclei were stained with DAPI.
